Losartan and Simvastatin Inhibit Platelet Activation in Hypertensive Patients
10.1007/s11239-005-0343-8 Cite this article as: Nomura, S., Shouzu, A., Omoto, S. et al. J Thromb Thrombolysis (2004) 18: 177. doi:10.1007/s11239-005-0343-8 Abstract Background: Diabetic patients also show hypercoagulability and platelet hyperaggregability, with increased levels of platelet activation-markers such as P-selectin (CD62P) and platelet-derived microparticles. We investigated the effects of losartan and simvastatin on circulating levels of platelet activation markers, microparticles, soluble selectins, and soluble cell adhesion molecules in hypertensive and hyperlipidemic patients with or without Type 2 diabetes. Methods: The subjects included 25 normotensive healthy controls and 41 hypertensive patients. The 41 hypertensive patients were divided into three groups: group A had hypertension and hyperlipidemia ( n = 11), group B had hypertension and Type 2 diabetes ( n = 14), and group C had hypertension, hyperlipidemia, and diabetes ( n = 16). Losartan was administered to all of the patients at a dose of 50 mg/day for 24 weeks. In addition, simvastatin was administered to the hyperlipidemic patients at a dose of 10 mg/day for 24 weeks. Results: There were significant differences in the levels of CD62P, CD63, PAC-1, platelet microparticles, endothelial microparticles, sE-selectin, and sVCAM-1 between the hypertensive patients and healthy controls. These markers were all significantly increased in hypertensive and hyperlipidemic patients with Type 2 diabetes. In hypertensive patients with diabetes, CD62P, CD63, PAC-1, platelet and endothelial microparticles, and soluble adhesion markers were all decreased by losartan monotherapy. The decrease of each marker in hypertensive and hyperlipidemic patients given combined therapy with losartan plus simvastatin was greater among those with than without Type 2 diabetes. Low-density lipoprotein was decreased significantly by simvastatin and was correlated with CD62P or platelet microparticles in all of the patients. Conclusion: Administration of losartan plus simvastatin to hypertensive and hyperlipidemic patients with Type 2 diabetes may prevent the development of cardiovascular complications caused by activated platelets and microparticles via another mechanism in addition to reduction of the blood pressure or lipid levels. Key Words platelet activation markers hypertension hyperlipidemia type 2 diabetes mellitus losartan simvastatin
This revised version was published online in May 2005 with a corrected cover date.
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten years cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects.
Pugh JA, Medina RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end-stage renal disease: More evidence for a tri-ethnic community.
Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55).
Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus.
Carmassi F, Morale M, Puccett R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.
Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control.
Cominacini L, Pasini AF, Garbin U, et al. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: Possible role of oxidative stress.
Schafer AI. The hypercoagulable states.
Ann Intern Med
Frade LJG, de la Calle H, Alava I, Navarro JL, Ceighton LJ, Gaffney PJ. Diabetes as a hypercoagulable state: Its relationship with fibrin fragments and vascular damage.
Tschope D, Esser J, Schwippert B, et al. Large platelets circulate in an activated state in diabetes.
Semin Thromb Haemost 1991;17:433–439.
Nomura S, Komiyama Y, Miyake T, et al. Amyloid β-protein precursor-rich platelet microparticles in thrombotic disease.
Nomura S. Functional and clinical significance of platelet- derived microparticles.
Int J Haematol 2001;74:397–404.
Nomura S, Suzuki M, Katsura K, et al. Platelet derived microparticles may influence the development of atherosclerosis in diabetes mellitus.
Nomura S, Shouzu A, Omoto S, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes.
Mattock MB, Barnes DJ, Viberti GC, et al. Microalbuninuria and coronary heart disease in non-insulin-dependent diabetes: An incidence study.
Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease.
Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency.
N Engl J Med
Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes.
J Am Soc Nephrol
Cheetham C, Collis J, O’Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin dependent diabetes.
J Am Coll Cardiol
Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation.
Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension.
Am J Cardiol
Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179.
Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in diabetes.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert commitee on the diagnosis and classification of diabetes mellitus.
Diabetes Care 1997;20:1183–1197.
Investigative Committee on Guidelines for the Diagnosis and Treatment of Hyperlipidemia, Japan Atherosclerosis Society. Guidelines for the Diagnosis and Treatment of Hyperlipidemia in Adults.
Murakami T, Komiyama Y, Masuda M, et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease.
Eur J Clin Invest
Nomura S, Nakamura T, Cone J, Tandon NN, Kambayashi J. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation.
Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant -containing microparticles.
Miyake T, Nomura S, Komiyama Y, et al.~Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation.
Combes V, Simon A, Grau G, et al.
generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.
J Clin Invest
Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis.
Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.
J Biol Chem
Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayshi J. High shear stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells.
Lindholm LH, Ibsen H, Dahlof B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endopoint reduction in hypertension study (LIFE): A randomised trial against atenolol.
Kjeldsen SE, Dahlof B, Devereux RB, et al. LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endopoint Reduction (LIFE) substudy.
Shahinfar S, Dickson TZ, Ahmed T, et al. For the RENAAL Investigators. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL study.
Wolf G, Schneider A, Helmchen U, Stahl RA. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis.
Hayek T, Aviram M, Heinrich R, Sakhnini E, Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients.
Biochem Biophys Res Commun
Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment.
Am J Cardiol
Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.
Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/Paxillin phosphorylation of human monocytes.
Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hyper-cholesterolemia.
J Am Coll Cardiol
Teupser D, Bruegel M, Stein O, Stein Y, Thiery J. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Biochem Biophys Res Commun
Serrano Jr CV, Yoshida VM, Venturinelli ML, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia.
Rezaie-Majd A, Maca T, Bucek RA, et al. Baghestanian. Simvastatin reduces expression of cytokines, interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.
Arterioscler Thromb Vasc Biol
Lefer DJ. Statins as potent antiinflammatory drugs.
Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment.
Cipollone F, Mezzetti A, Porreca E, et al. Davi. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia–-effects of statin therapy.
Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue–factor-mediated thrombin generation by simvastatin.
Lee IT, Sheu WHH, Lin SY, Lee WJ, Song YM, Liu HC. Simvasatatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia.
J Diabet Complicat
Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days–-an effect independent of low-density lipoprotein cholesterol reduction.
Tsakiris DA, Keller U, Zulewski H, Miserez AR, Wolf F, Marbet GA. Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein B.
Eur J Clin Pharmacol
Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
J Am Coll Cardiol
Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function.
Arterioscler Thromb Vasc Biol
Zoja C, Corna D, Rottoli D, et al. Remuzzi. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
CrossRef PubMed Copyright information
© Springer Science + Business Media, Inc. 2004